SB 1039 (see companion bill HB 1324) – Maryland
Status: Inactive / DeadYear Introduced: 2019
Link: http://mgaleg.maryland.gov/webmga/frmMain.aspx?id=sb1039&stab=01&pid=billpage&tab=subject3&ys=2019RS
Requiring the Maryland Medical Assistance Program to establish reimbursement levels, rather than maximum reimbursement levels, for certain drug products; requiring that certain minimum reimbursement levels be at least equal to the National Average Drug Acquisition Cost of the generic product plus a certain fee-for-service professional dispensing fee; providing that certain provisions of the Act apply to managed care organizations that use pharmacy benefits managers to manage prescription drug coverage; etc.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
Associated Litigation:
No items found